For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Research and development | 9,734 | 10,551* | 10,673 | 12,218 |
| General and administrative | 4,741 | 4,730* | 4,475 | 4,843 |
| Total operating expenses | 14,475 | 15,281 | 15,148 | 17,061 |
| Loss from operations | -14,475 | -15,281* | -15,148 | -17,061 |
| Other income (expense), net | - | -2* | 0 | 0 |
| Interest income | 920 | 1,375* | 1,269 | 1,386 |
| Total other income, net | 920 | 1,373* | 1,269 | 1,386 |
| Net loss | -13,555 | -13,909* | -13,879 | -15,675 |
| Unrealized gain (loss) on short-term investments | - | -14* | - | - |
| Comprehensive loss | - | -13,923 | - | - |
| Basic EPS | -0.6 | -0.623 | -0.62 | -0.7 |
| Diluted EPS | -0.6 | -0.623 | -0.62 | -0.7 |
| Basic Average Shares | 22,407,000 | 22,338,000 | 22,386,000 | 22,356,000 |
| Diluted Average Shares | 22,407,000 | 22,338,000 | 22,386,000 | 22,356,000 |
Boundless Bio, Inc. (BOLD)
Boundless Bio, Inc. (BOLD)